성인 고형암 환자의 고칼슘혈증 치료현황과 치료효과 분석
Real-world Treatment Pattern and Outcomes of Hypercalcemia among Solid Tumor Patients
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Hypercalcemia is an important metabolic emergency condition in cancer patients. Bisphosphonate is the treatment of choice for hypercalcemia, whereas calcitonin and hydration with furosemide are recommended for acute supportive therapy. However, data regarding real-world treatment patterns and outcomes of pharmacological treatments are limited. Therefore, we aimed to investigate the treatment patterns and clinical outcomes of hypercalcemia treatment in solid tumor patients. Methods: Electronic medical records of 123 adults with solid cancers and albumin-corrected calcium levels >10.5 mg/dL or ionized calcium levels >1.35 mmol/L were reviewed. We retrospectively analyzed the pharmacological treatment and recovery rate according to the severity of hypercalcemia. Results: A total of 177 cases were identified, of which 49 were not treated and 30 were treated with hydration only. In moderate-to-severe cases, 86.5% received pharmacological treatment. Thirty-four cases (19.2%) were treated with bisphosphonate alone and 58 cases (32.8%) were treated with bisphosphonate and calcitonin. In mild hypercalcemia cases, the recovery rate was higher for those receiving hydration only or pharmacological treatment (79.7%) than for those receiving no treatment (61.4%, p = 0.041). Most moderate-to-severe cases were treated with medication and of those treated, 56.3% recovered. The recovery rate was lower in those treated with bisphosphonate alone (38.2%) than in those who underwent calcitonin combination treatment (73.7%, p = 0.001). Conclusions: Bisphosphonate combined with calcitonin was found to be more effective than bisphosphonate alone for the treatment of moderate-to-severe hypercalcemia. Considering the current shortage of calcitonin, further efforts are required to ensure its stable supply.
Abstract
Background: Hypercalcemia is an important metabolic emergency condition in cancer patients. Bisphosphonate is the treatment of choice for hypercalcemia, whereas calcitonin and hydration with furosemide are recommended for acute supportive therapy. However, data regarding real-world treatment patterns and outcomes of pharmacological treatments are limited. Therefore, we aimed to investigate the treatment patterns and clinical outcomes of hypercalcemia treatment in solid tumor patients. Methods: Electronic medical records of 123 adults with solid cancers and albumin-corrected calcium levels >10.5 mg/dL or ionized calcium levels >1.35 mmol/L were reviewed. We retrospectively analyzed the pharmacological treatment and recovery rate according to the severity of hypercalcemia. Results: A total of 177 cases were identified, of which 49 were not treated and 30 were treated with hydration only. In moderate-to-severe cases, 86.5% received pharmacological treatment. Thirty-four cases (19.2%) were treated with bisphosphonate alone and 58 cases (32.8%) were treated with bisphosphonate and calcitonin. In mild hypercalcemia cases, the recovery rate was higher for those receiving hydration only or pharmacological treatment (79.7%) than for those receiving no treatment (61.4%, p = 0.041). Most moderate-to-severe cases were treated with medication and of those treated, 56.3% recovered. The recovery rate was lower in those treated with bisphosphonate alone (38.2%) than in those who underwent calcitonin combination treatment (73.7%, p = 0.001). Conclusions: Bisphosphonate combined with calcitonin was found to be more effective than bisphosphonate alone for the treatment of moderate-to-severe hypercalcemia. Considering the current shortage of calcitonin, further efforts are required to ensure its stable supply.
참고문헌 (15)
- Minisola S, "The diagnosis and management of hypercalcaemia", BMJ, 350, pp.h2723~ (2015)
- Fallah-Rad N, "Managing hypercalcaemia and hypocalcaemia in cancer patients", Curr Opin Support Palliat Care, 7(3), pp.265~271 (2013)
- Stewart AF, "Clinical practice. Hypercalcemia associated with cancer", N Engl J Med, 352(4), pp.373~379 (2005)
- Sternlicht H, "Hypercalcemia of malignancy and new treatment options", Ther Clin Risk Manag, 11, pp.1779~1788 (2015)
- Ralston SH, "Cancerassociated hypercalcemia: Morbidity and mortality: clinical experience in 126 treated patients", Ann Intern Med, 112(7), pp.499~504 (1990)
- Lewis MA, "Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment", CA Cancer J Clin, 61(5), pp.287~314 (2011)
- Bilezikian JP, "Management of Acute Hypercalcemia", N Engl J Med, 326(18), pp.1196~1203 (1992)
- Thosani S, "Denosumab: a new agent in the management of hypercalcemia of malignancy", Future Oncol, 11(21), pp.2865~2871 (2015)
- Goldner W, "Cancer-Related Hypercalcemia", J Oncol Pract, 12(5), pp.426~432 (2016)
- Clines GA, "Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone", Endocr Relat Cancer, 12(3), pp.549~583 (2005)
- Major P, "Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials", J Clin Oncol, 19(2), pp.558~567 (2001)
- Wright JD, "Quality and Outcomes of Treatment of Hypercalcemia of Malignancy", Cancer Invest, 33(8), pp.331~339 (2015)
- Plach K, "Retrospective chart evaluation of hypercalcemia management in oncology patients at the University of Chicago Medical Center", J Oncol Pharm Pract, 2017, pp.1078155217733808~ (2017)
- Thiébaud DD, "Fast and effective treatment of malignant hypercalcemia: Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate", Arch Intern Med, 150(10), pp.2125~2128 (1990)
- Ralston SH, "Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin", Br Med J (Clin Res Ed), 292(6535), pp.1549~1550 (1986)